Clinical Trials
93 trialsPTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Stanford University
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Novo Nordisk A/S
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Fujifilm Pharmaceuticals U.S.A., Inc.
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
BerGenBio ASA
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Astellas Pharma Inc
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Celgene
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
M.D. Anderson Cancer Center
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
Astex Pharmaceuticals, Inc.
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
M.D. Anderson Cancer Center
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
TJ Biopharma Co., Ltd.
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
University Hospital, Basel, Switzerland
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
OncoVerity, Inc.
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Canadian Cancer Trials Group
IMG-7289-CTP-101
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
University of Washington
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
PACT
Wuerzburg University Hospital
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCordĀ® & UNM CBU to Patients With Hematological Malignancies
Gamida Cell ltd
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Traws Pharma, Inc.
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Duke University
Transplantation of NiCordĀ®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell ltd
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Masonic Cancer Center, University of Minnesota
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Novartis
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
National Institutes of Health Clinical Center (CC)
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Regimmune Corporation
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
University of Texas Southwestern Medical Center
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
National Institutes of Health Clinical Center (CC)
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Case Comprehensive Cancer Center
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
BioMed Valley Discoveries, Inc
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Celgene
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
M.D. Anderson Cancer Center
PKC412 and 5-Azacytidine
M.D. Anderson Cancer Center
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
Cell Medica Ltd
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Case Comprehensive Cancer Center
Improving Blood Stem Cell Collection and Transplant Procedures
National Institutes of Health Clinical Center (CC)
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
University of Michigan Rogel Cancer Center
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
Masonic Cancer Center, University of Minnesota